|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al; North-East Japan Study Group. Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 20;368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hilberg F, Roth GJ, Krssak M, Kautschitsch
S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel
A, Quant J, et al: BIBF 1120: triple angiokinase inhibitor with
sustained receptor blockade and good antitumor efficacy. Cancer
Res. 15;68:4774–4782. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Richeldi L, Costabel U, Selman M, Kim DS,
Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G,
et al: Efficacy of a tyrosine kinase inhibitor in idiopathic
pulmonary fibrosis. N Engl J Med. 22;365:1079–1087. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. N Engl J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reck M, Kaiser R, Mellemgaard A, Douillard
JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I,
Liao M, et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib
versus docetaxel plus placebo in patients with previously treated
non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind,
randomised controlled trial. Lancet Oncol. 15:143–155. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitamura K, Seike M, Okano T, Matsuda K,
Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K and Gemma A:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014. View Article : Google Scholar
|
|
19
|
Seike M, Yanaihara N, Bowman ED, Zanetti
KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J,
Shibata T, et al: Use of a cytokine gene expression signature in
lung adeno-carcinoma and the surrounding tissue as a prognostic
classifier. J Natl Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimokawa T, Seike M, Soeno C, Uesaka H,
Miyanaga A, Mizutani H, Kitamura K, Minegishi Y, Noro R, Okano T,
et al: Enzastaurin has anti-tumour effects in lung cancers with
over-expressed JAK pathway molecules. Br J Cancer. 106:867–875.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bustin SA: Absolute quantification of mRNA
using real-time reverse transcription polymerase chain reaction
assays. J Mol Endocrinol. 25:169–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugano T, Seike M, Noro R, Soeno C, Chiba
M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, et al:
Inhibition of ABCB1 overcomes cancer stem cell-like properties and
acquired resistance to MET inhibition in non-small lung cancer. Mol
Cancer Ther. 14:2433–2440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yauch RL, Januario T, Eberhard DA, Cavet
G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al:
Epithelial versus mesenchymal phenotype determines in vitro
sensitivity and predicts clinical activity of erlotinib in lung
cancer patients. Clin Cancer Res. 11:8686–8698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kutluk Cenik B, Ostapoff KT, Gerber DE and
Brekken RA: BIBF 1120 (nintedanib), a triple angiokinase inhibitor,
induces hypoxia but not EMT and blocks progression of preclinical
models of lung and pancreatic cancer. Mol Cancer Ther. 12:992–1001.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar
|
|
28
|
Casanovas O, Hicklin DJ, Bergers G and
Hanahan D: Drug resistance by evasion of antiangiogenic targeting
of VEGF signaling in late-stage pancreatic islet tumors. Cancer
Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian X, Anzovino A, Kim S, Suyama K, Yao
J, Hulit J, Agiostratidou G, Chandiramani N, McDaid HM, Nagi C, et
al: N-cadherin/FGFR promotes metastasis through
epithelial-to-mesenchymal transition and stem/progenitor cell-like
properties. Oncogene. 33:3411–3421. 2014. View Article : Google Scholar :
|
|
30
|
Nguyen PT, Tsunematsu T, Yanagisawa S,
Kudo Y, Miyauchi M, Kamata N and Takata T: The FGFR1 inhibitor
PD173074 induces mesenchymal-epithelial transition through the
transcription factor AP-1. Br J Cancer. 109:2248–2258. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DeMaio L, Buckley ST, Krishnaveni MS,
Flodby P, Dubourd M, Banfalvi A, Xing Y, Ehrhardt C, Minoo P, Zhou
B, et al: Ligand-independent transforming growth factor-β type I
receptor signalling mediates type I collagen-induced
epithelial-mesenchymal transition. J Pathol. 226:633–644. 2012.
View Article : Google Scholar
|
|
32
|
Kage H and Borok Z: EMT and interstitial
lung disease: A mysterious relationship. Curr Opin Pulm Med.
18:517–523. 2012.PubMed/NCBI
|
|
33
|
Yang S, Banerjee S, de Freitas A, Sanders
YY, Ding Q, Matalon S, Thannickal VJ, Abraham E and Liu G:
Participation of miR-200 in pulmonary fibrosis. Am J Pathol.
180:484–493. 2012. View Article : Google Scholar :
|
|
34
|
Minegishi Y, Sudoh J, Kuribayasi H,
Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The
safety and efficacy of weekly paclitaxel in combination with
carboplatin for advanced non-small cell lung cancer with idiopathic
interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar
|
